The interview provides a US-centric, longitudinal view of cervical cancer treatment evolution, highlighting the transition from chemotherapy alone to immunotherapy-based standards in both locally advanced and metastatic disease. Despite meaningful improvements in first-line outcomes, the discussion underscores a steep drop-off in effective options beyond initial therapy, particularly after IO exposure. Future advances are expected to be incremental rather than transformative, with ADCs representing the most realistic near-term opportunity to address ongoing unmet need.

This interview was conducted on 18 November 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.